Details for Patent: 5,817,642
✉ Email this page to a colleague
| Title: | Clearing of atherosclerosis |
| Abstract: | A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from hyaluronic acid, salts thereof, homologues, analogues, derivatives, esters, complexes, fragments and subunits. |
| Inventor(s): | Falk; Rudolf Edgar (Toronto, CA), Asculai; Samuel Simon (Toronto, CA) |
| Assignee: | Hyal Pharmaceutical Corporation (Mississauga, CA) |
| Filing Date: | Aug 15, 1995 |
| Application Number: | 08/464,769 |
| Claims: | 1. A method of clearing atherosclerosis comprising the step of administering to a patient, at least one dosage amount of a pharmaceutical composition comprising an effective non-toxic amount of each of a chelating agent, a non-steroidal anti-inflammatory drug (NSAID), an anti-oxidant and a form of hyaluronic acid, selected from the group consisting of hyaluronic acid and its non-toxic salts. 2. The method of claim 1 wherein the form of hyaluronic acid is sodium hyaluronate having a molecular weight less than about 750,000 daltons. 3. The method of claim 2 wherein the at least one dosage amount comprising a plurality of dosage amounts administered intravenously at suitable intervals over a period of time. 4. The method of claim 3 wherein the chelating agent is EDTA. 5. The method of claim 3 wherein the NSAID is selected from the group consisting of diclofenac, tromethamine salt of ketoralac, indomethacin, piroxicam, and ibuprofen. 6. The method of claim 3 wherein the anti-oxidant is Vitamin C. 7. The method of claim 2 wherein the at least one such dosage amount comprises (i) about 1-3 gm of the chelating agent/70 kg person; (ii) about 15-30 mg of an NSAID; (iii) about 12-50 gm anti-oxidant; and (iv) between about 50 mg to well in excess of 1000 mg of the form of hyaluronic acid; in sterile water. 8. The method of claim 3 wherein the at least one such dosage amount comprises (i) about 1-3 gm of the chelating agent/70 kg person; (ii) about 15-30 mg of an NSAID; (iii) about 12-50 gm anti-oxidant; and (iv) between about 50 mg to well in excess of 1000 mg of the form of hyaluronic acid; in sterile water. 9. The method of claim 7 or 8 wherein the chelating agent is EDTA. 10. The method of claim 7 or 8 wherein the NSAID is selected from the group consisting of diclofenac sodium and tromethamine salt of ketoralac. 11. The method of claim 7 or 8 wherein the anti-oxidant is selected from 12.5 to 25 gm of Vitamin C. 12. The method of claim 7 or 8 wherein the amount of sodium hyaluronate exceeds 200 mg. 13. The method of claim 7 or 8 wherein the amount of sodium hyaluronate is about 100 to about 120 mg, and the sodium hyaluronate has a molecular weight of about 150,000-225,000 daltons. 14. The method of claim 7 or 8 wherein the dosage amount further comprises 200 ml of sterile water. 15. The method of claim 7 or 8 wherein the dosage amount further comprises an effective amount of a local anesthetic. 16. The method of claim 15 wherein the dosage amount further comprises an effective amount of bicarbonate of soda. |
